Some considerations in the treatment of CAR-T cell for cancer
10.3872/j.issn.1007-385X.2018.09.003
- VernacularTitle:CAR-T细胞肿瘤治疗中若干问题的思考
- Author:
ZHAO Lingdi
1
,
2
;
HAN Lu
1
,
2
;
GAO Quanli
1
,
2
Author Information
1. (Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University &
2. Henan Provincial Cancer Hospital
- Publication Type:Journal Article
- Keywords:
chimeric antigen receptor modified T (CAR-T) cell;
immunotherapy;
combination;
adverse events
- From:
Chinese Journal of Cancer Biotherapy
2018;25(9):859-864
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor modified T (CAR-T) cell therapy has achieved excellent clinical efficacy in patients with hematological malignancies (especially for patients with CD19 positive), and is regarded as a major advance in cancer therapy in recent years. It aroused scientists’strong interest in developing CAR-T cell products for the treatment of cancers. However, there are still some problems in the treatment of CAR-T cells. For examples, some patients lose the opportunity of CAR-T cell therapy while waiting for CAR-T cell culture, some unique adverse events during treatment of CAR-T cell therapy may endanger the patients’life, and the efficacy of CAR-T cell therapy is unsatisfactory on solid tumors. Even for hematological malignancies, some patients will eventually relapse and lead to treatment failure. Therefore, exploring methods to improve the efficacy, diagnosis the unique adverse events of CAR-T cell therapy early and give appropriately management, expand potentially benefiting populations of CAR-T cell therapy are issues that need to be addressed in current CAR-T cell therapy research.
- Full text:20180903.pdf
